Abstract

Targeting the alpha-v beta-3 integrin receptor holds promise for active targeting in cancer therapy and imaging diagnostics. Cyclic (arginine-glycine-aspartate-phenylalanine-lysine), an arginylglycylaspartic acid tumor-targeting peptide, has shown efficient selective binding to the alpha-v beta-3 integrin receptor, making it a highly effective ligand. Its potential for active targeting in drug delivery has garnered significant attention, leading to extensive research and development efforts. This paper provides a comprehensive review of the application of the cyclic (arginine-glycine-aspartate-phenylalanine-lysine) in nanoparticle-mediated drug delivery systems, aiming to serve as a valuable reference for the expedited development of active targeting formulations. This article explores the utilization of cyclic (arginine-glycine-aspartate-phenylalanine-lysine) as a targeting ligand in these systems and discusses its role, either as the sole ligand or in combination with others, in enhancing the precision of drug delivery to specific lesion sites, with a primary focus on tumors. This paper describes the current status of cyclic (arginine-glycine-aspartate-phenylalanine-lysine)-modified nanoparticles in various carrier materials for targeted therapy, molecular imaging, cytotoxic peptide delivery, photosensitizer delivery, and modified biomaterials. The strategic manipulation of drug distribution and pharmacokinetic properties aims to optimize therapeutic outcomes while minimizing systemic side effects, showcasing the potential of cyclic (arginine-glycine-aspartate-phenylalanine-lysine)-modified nanoparticle systems in advancing precision medicine.